Phaseline

Companies › Oorja Bio

Oorja Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ORJ-001
β1 integrin agonist peptide
ITGB1Phase 2Idiopathic Pulmonary FibrosisJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07869147ORJ-001Phase 2Idiopathic Pulmonary FibrosisRespiratoryJan 2029

Targets

ITGB1 (1)

Companies with the same targets

–

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.